rhG-CSF在小儿ANLL强烈化疗中的应用

为探讨rhG-CSF对小儿ANLL强烈化疗后粒细胞缺乏的疗效，采用AAE方案（ADM、Ara-C、VP(16)或VM(26)），化疗后当WBC＜1×109/L或ANC＜0．5×109/L时，给予rhG-CSF200μg/m2·d（5～10μg/kg·d），皮下注射，一般连续5～10天。本文15例ANLL，用rhG-CSF30例次。用rhG-CSF前，WBC平均0．78×109/L、ANC0．15×109/L。用rhG-CSF后，平均6．5天WBC升至＞3×109/L、ANC升至＞1×109/L。粒细胞恢复时间与对照组相比明显缩短（P＜0．01）。骨髓复查未见原始细胞增多或复发。rhG-CSF有促进强烈化疗所致骨髓抑制和粒细胞缺乏的恢复，但未见骨髓原始细胞增多和白血病复发。

APPLICATION OF rhG-CSF ON INTENSIVE CHEMOTHERAPY IN CHILDREN WITH ACUTE NON-LYMPHOBLASTIC LEUKEMIA

To determine the effect of rhG-CSF on granulocytopenia after intensive chemotherapy in children with acute non-lymphoblastic leukemia (ANLL). Methods: The intensive chemotherapy protocol was AAE(ADM,Ara-C, VP16 or VM26). 200μg/m. d (5-10μg/kg·d)rhG-CSF was given hypodermatically for 5-10 days consecutively when WBC was below 1 ×109/L or ANC below 0.5×109/L after chemotherapy. Results: 30 cases of rhG-CSF was given hypodermatically in 15 patients with ANLL. Averagely WBC and ANC was 0. 78×109/L and 0.15×109/L respectively before rhG-CSF was given. WBC increased to 3×109/L and ANC increased to 1×109/L both within 6.5 days wihn rhG-CSF was used. There was great significance in the recovery granulocyte as compared with the contrast group (p＜0.01). Bone　marrow re-examination revealed no leukemia relapse or increase of blast cells. Conclusion:rhG-CSF has the potential to accelerate the recovery of depressed marrow and granulocytopenia after intensive chemotherapy with no leukemia relapse or bone marrow blast cells increase.